Other grades of this product :
| PTH (1-84) (HUMAN) Basic information |
| Product Name: | PTH (1-84) (HUMAN) | | Synonyms: | H-SER-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ASN-SER-MET-GLU-ARG-VAL-GLU-TRP-LEU-ARG-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE-VAL-ALA-LEU-GLY-ALA-PRO-LEU-ALA-PRO-ARG-ASP-ALA-GLY-SER-GLN-ARG-PRO-ARG-LYS-LYS-GLU-ASP-ASN-VAL-LEU-VAL-GLU-SER-HIS-GLU-LYS-SER-LEU-GLY-GLU-ALA-ASP-LYS-ALA-ASP-VAL-ASN-VAL-LEU-THR-LYS-ALA-LYS-SER-GLN-OH;parathyroid hormone(1-84);PARATHYROID HORMONE(1-84) HUMAN 50 UG*;Parathormone, PTH;PTH, HUMAN;PTH (1-84) (HUMAN);PTH (HUMAN, 1-84);SER-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ASN-SER-MET-GLU-ARG-VAL-GLU-TRP-LEU-ARG-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE-VAL-ALA-LEU-GLY-ALA-PRO-LEU-ALA-PRO-ARG-ASP-ALA-GLY-SER-GLN-ARG-PRO-ARG-LYS-LYS-GLU-ASP-ASN-VAL-LEU-VAL-GLU-SER-HIS-GLU-LYS-SER-LEU-GLY-GLU-ALA-ASP-LYS-ALA-ASP-VAL-ASN-VAL-LEU-THR-LYS-ALA-LYS-SER-GLN | | CAS: | 68893-82-3 | | MF: | C408H674N126O126S2 | | MW: | 9424.62 | | EINECS: | 282-361-6 | | Product Categories: | | Mol File: | Mol File |
| PTH (1-84) (HUMAN) Chemical Properties |
| storage temp. | −20°C | | form | powder |
| PTH (1-84) (HUMAN) Usage And Synthesis |
| Uses | Treatment of
osteoporosis, as an antiosteoporotic, in the treatment of
bone and mineral disease and disorders, bone metabolism
regulator, blood calcium regulator, and as a diagnostic aid
(pseudohypoparathyroidism; hypocalcemia). | | Indications | Human rPTH (1-34) has been produced by recombinant
technologies, is now approved, and will soon be available
for the treatment of osteoporosis. It is given subcutaneously,
25 μg/day cyclically for 12 to 18 months, to increase
bone density in individuals with a history of fractures,
severe osteopenia, or osteoporosis. PTHrP (1-36)
has also been synthesized and is in early clinical trials. | | Brand name | Paroidin (Parke-Davis). |
| PTH (1-84) (HUMAN) Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye